Barry Weinstock, MD
Interventional Cardiology · Altamonte Springs, FLNPI 1548213200
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (31.6%), food and beverage and ownership interests — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Medtronic at 37.7% of the total. Reporting peaked in 2019 at $82,082 and has fallen 93.8% since, to $5,050 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $230.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$59K
- Penumbra, Inc.$19K
- Boston Scientific$16K
- Angiodynamics, Inc.$15K
- Idev Technologies, Inc.$8K
- Inari Medical, Inc.$8K
- plus $32K from 52 others
Across 2 payments — averaging $13,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$24K
- Atrium Medical Corporation$3K
What the payments were for
- Royalty or licence$49,36832%
- Consulting fees$21,02513%
- Speaking & faculty fees$8,5255%
- Travel & lodging$12,3288%
- Food & beverage$37,38424%
- Education$3,1512%
- Ownership interest$24,33016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$49,368
- GENERAL - THERAPIES$16,230
- Auryon$15,056
- Indigo$7,550
- CAT RX$7,175
- FLOWTRIEVER CATHETER, S$6,485
- Impella$6,264
- CT THROMBECTOMY SYSTEM KIT$5,206
- Indigo System$3,338
- Barostim Neo System$2,109
- BioMonitor$1,407
- FlowTriever$1,204
- VIABAHN VBX Balloon Expandable Endoprosthesis$1,125
- CardioMEMS HF System$630
- HawkOne$544
- Tack Endovascular System$418
- IN.PACT Admiral$389
- Penumbra System$369
- Acticor 7 VR-T DX$343
- Micra$319
How this compares
$156,111 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 351 | $382,670 |
| EntrestoSacubitril/Valsartan | 82 | $104,508 |
| Repatha SureclickEvolocumab | 86 | $83,285 |
| XareltoRivaroxaban | 68 | $66,516 |
| JardianceEmpagliflozin | 33 | $54,563 |
| Praluent PenAlirocumab | 35 | $25,679 |
| BrilintaTicagrelor | 33 | $22,153 |
| MounjaroTirzepatide | 14 | $14,635 |
| Ranolazine ErRanolazine | 36 | $6,989 |
| Ezetimibe | 208 | $3,994 |
| Valsartan | 99 | $3,769 |
| Rosuvastatin Calcium | 303 | $3,755 |
| Atorvastatin Calcium | 400 | $3,581 |
| Metoprolol Succinate | 206 | $3,330 |
| ClopidogrelClopidogrel Bisulfate | 255 | $2,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $273 | $382,670351 claims |
| NovartisEntresto | $339 | $104,50882 claims |
| Johnson & JohnsonXarelto | $171 | $66,51668 claims |
| Boehringer IngelheimJardiance | $117 | $54,56333 claims |
| AstraZenecaBrilinta | $24 | $22,15333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Altamonte Springs
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.